within Pharmacolibrary.Drugs.ATC.S;

model S01AD06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.003,
    adminDuration  = 600,
    adminMass      = 0.015,
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Vidarabine (adenine arabinoside, Ara-A) is an antiviral compound used primarily in the past for the treatment of herpes simplex virus (HSV) infections, especially in immunocompromised patients and for herpes simplex encephalitis. It has largely been replaced by acyclovir and other antivirals and is not commonly used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients following intravenous administration.</p><h4>References</h4><ol><li>Lauren A Sadowski, Rista Upadhyay, Zachary W Greeley, Barry J Margulies,Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2.,Viruses,2021<a href='https://pubmed.ncbi.nlm.nih.gov/34202050/'>https://pubmed.ncbi.nlm.nih.gov/34202050/</a></li><li>F Fauvelle, A LÃ©on, P Nicolas, M Tod, L Guillevin, O Petitjean,Pharmacokinetics of vidarabine in the treatment of polyarteritis nodosa.,Fundamental & clinical pharmacology,1992<a href='https://pubmed.ncbi.nlm.nih.gov/1348236/'>https://pubmed.ncbi.nlm.nih.gov/1348236/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01AD06;
